World

Former Google CEO warns that AI will threaten humanity in the next 5 years

Nov 30, 2023

New York [US], November 30: Former Google CEO Eric Schmidt said that the power of artificial intelligence (AI) could threaten humanity in the next 5-10 years and companies are not doing enough to prevent it.
Interviewed at an Axios AI event on November 28, former Google CEO Eric Schmidt compared AI development to nuclear weapons at the end of World War 2. After the US dropped two atomic bombs on Nagasaki and Nagasaki. Japan's Hiroshima in 1945 took 18 years for a treaty banning nuclear weapons testing to come into being, but according to Mr. Schmidt, "we don't have that kind of time now."
Mr. Schmidt believes that the dangers of AI will begin when computers can make their own decisions. Two years ago, experts warned that AI could threaten humanity in 20 years, but now, Mr. Schmidt said experts predict the danger could come in the next 2-4 years. He himself forecasts the next 5-10 years.
According to the former CEO of Google, a global organization is needed, with a model similar to the Intergovernmental Panel on Climate Change, to provide accurate information to policymakers about the urgency of the issue. .
Less than a month earlier, US President Joe Biden signed an executive order on AI, requiring many new measures to ensure safety, privacy, worker protection and innovation, setting standards. in AI development. Google has also launched an AI tool called Bard , a product that competes with OpenAI's popular chatbotChatGPT.
Despite giving warnings, Mr. Schmidt also believes that AI can be a useful tool for humanity, such as in the fields of health or education. "I challenge you to prove that AI doctors or AI tutors are negative. It will be good for the world," said the former Google CEO.
Source: ThanhNien Newspaper

More news

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

Tampa (Florida) [US], January 7: Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooNAngioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD). The 1-year data was presented by Principal Investigator Prof. Ulf Teichgraber at the TCT USA 2024 conference in a Late-Breaking Clinical Trials Session (LBCT). Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in femoropopliteal interventions.

Jan 07, 2025